- Excipient Compatibility khuranahbc 2008-11-27 07:25
- WHO - Generics as counterfeit BE 2008-11-24 07:21
- Significance level in Stability Analysis Ravi 2008-11-20 12:50
- Significance level in Stability Analysis d_labes 2008-11-20 15:11
- Significance level in Stability Analysis Helmut 2008-11-20 15:37
- Significance level in Stability Analysis Ravi 2008-11-21 05:16
- Significance level in Stability Analysis Ravi 2008-11-21 06:01
- Significance, power, hypotheses - what does it all mean d_labes 2008-11-21 09:34
- Significance level in Stability Analysis Helmut 2008-11-20 15:37
- Significance level in Stability Analysis martin 2008-11-21 10:33
- Significance level in Stability Analysis d_labes 2008-11-20 15:11
- reg IRB drshayana 2007-03-08 10:31
- reg IRB Dr.Tarak Parikh 2007-04-05 08:40
- reg IRB drshiv 2007-04-07 19:02
- reg IRB hitesh shah 2007-04-09 09:40
- reg IRB Dr.Tarak Parikh 2007-04-09 13:19
- reg IRB Ohlbe 2007-04-09 23:54
- reg IRB Ohlbe 2007-04-10 10:26
- reg IRB hitesh shah 2007-04-11 06:48
- reg IRB Ohlbe 2007-04-11 11:02
- reg IRB hitesh shah 2007-04-12 08:43
- reg IRB sureshcology 2008-10-28 06:15
- Control of IRB/IECs Ohlbe 2008-10-28 16:42
- Control of IRB/IECs sureshcology 2008-10-29 04:12
- IECs in France Ohlbe 2008-10-29 22:42
- Germany H_Rotter 2008-10-29 23:09
- Germany sureshcology 2008-10-30 04:35
- Control of IRB/IECs sureshcology 2008-10-29 04:12
- Control of IRB/IECs Ohlbe 2008-10-28 16:42
- reg IRB sureshcology 2008-10-28 06:15
- reg IRB hitesh shah 2007-04-12 08:43
- reg IRB (India) Sasi 2008-11-21 07:54
- reg IRB Ohlbe 2007-04-11 11:02
- reg IRB (Canada) M.Vasu 2007-05-04 15:51
- reg IRB (Canada) Dr.Tarak Parikh 2007-05-15 09:40
- reg IRB Ohlbe 2007-04-09 23:54
- reg IRB Dr.Tarak Parikh 2007-04-09 13:19
- reg IRB hitesh shah 2007-04-09 09:40
- reg IRB drshiv 2007-04-07 19:02
- reg IRB Dr.Tarak Parikh 2007-04-05 08:40
- EMEA-Individual Product BE guidelines BE 2008-11-18 13:14
- No EMEA-Individual Product BE guidelines Helmut 2008-11-18 13:26
- No EMEA-Individual Product BE guidelines ElMaestro 2008-11-18 13:39
- No EMEA-Individual Product BE guidelines Helmut 2008-11-18 14:00
- No EMEA-Individual Product BE guidelines Ohlbe 2008-11-18 22:02
- No EMEA-Individual Product BE guidelines Helmut 2008-11-18 14:00
- No EMEA-Individual Product BE guidelines ElMaestro 2008-11-18 13:39
- No EMEA-Individual Product BE guidelines Helmut 2008-11-18 13:26
- Randomization schedule vish14184 2008-11-04 09:44
- Randomization before EC Approval Helmut 2008-11-04 11:57
- Randomization schedule ElMaestro 2008-11-04 12:16
- Randomization schedule mbshankar 2008-11-18 11:38
- monelukast sodium talr 2008-11-09 16:11
- monelukast sodium JPL 2008-11-10 09:58
- Montelukast sodium talr 2008-11-10 10:16
- Montelukast sodium JPL 2008-11-13 15:02
- Montelukast sodium Ohlbe 2008-11-13 15:42
- Montelukast sodium talr 2008-11-15 12:54
- Montelukast sodium Ohlbe 2008-11-13 15:42
- Montelukast sodium JPL 2008-11-13 15:02
- Montelukast sodium talr 2008-11-10 10:16
- monelukast sodium JPL 2008-11-10 09:58
- Terminated study sanil 2008-11-04 14:29
- Terminated study Ohlbe 2008-11-04 15:54
- ICF consent vish14184 2008-11-04 09:57
- ICF consent Ohlbe 2008-11-04 14:03
- form 1572 krishnamurthy ca 2008-10-22 05:21
- AUC 0-infinity native circulating drugs (i,e, L-Thyroxin) Sally Odeh 2008-10-21 11:37
- Endogenous compounds Helmut 2008-10-21 20:05
- Comparisons of TPD, FDA and EMEA sukimmm 2008-10-20 03:00
- Comparisons of TPD, FDA and EMEA Helmut 2008-10-20 11:17
- Comparisons of TPD, FDA and EMEA sukimmm 2008-10-20 17:34
- Comparisons of TPD, FDA and EMEA Helmut 2008-10-20 11:17
- protocol for evaluating condoms alinpharma 2008-10-16 05:01
